Author: Ravi Shankar

BEIJING, Oct. 26, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced its third quarter 2026 results and business highlights for the nine-months ended September 30, 2026.

In the first three quarters of 2026, driven by strong commercial execution and global business development collaborations, the Company’s revenue grew 88.2% year-on-year (YoY) to RMB 2.1 billion, and net profit reached RMB 648.3 million, as the Company sustained profitability.

The Company also continued to accelerate its globalization, entering into a strategic collaboration with Eli Lilly that reflects global recognition of its innovation capabilities. The company has been continuously accelerating its pipeline development, with 14 registrational clinical trials ongoing and five new molecules entering the clinic this year. InnoCare further advanced its strategy of innovation, commercialization and globalization, building stronger momentum for long-term growth.

Financial Highlights

Revenue grew by 88.2% YoY to RMB 2.1 billion in the first three quarters of 2026, driven mainly by robust commercial growth and global business development collaborations.

Drug sales increased by 41.5% YoY to RMB 1.4 billion for the 9 months ended September 30, 2026, driven by robust growth of orelabrutinib and contributions from the newly launched tafasitamab and zurletrectinib.

Profit reached RMB 648.3 million, compared with a loss of RMB 72.0 million in the same period, mainly due to continued commercial growth and global BD collaborations.

Research and Development Investment increased by 16.1% YoY to RMB 785.1 million for the 9 months ended September 30, 2026, reflecting the advancement of additional Phase III clinical trials, as well as increased investment in new technology platforms.

Accelerating Globalization

In the third quarter of 2026, InnoCare continued to accelerate its globalization by entering into a strategic research collaboration and license agreement with Eli Lilly. Leveraging its drug discovery platform and extensive research experience, the Company will discover and advance up to five innovative target programs, with a total deal value of up to US$ 3.35 billion. The collaboration underscores global recognition of the Company’s R&D capabilities and the international competitiveness of its drug discovery platform.

Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “In the first three quarters of 2026, we sustained profitability, maintained robust commercial growth, and accelerated globalization. Our collaboration with Zenas continued to advance with increasing value realization, and we entered into a strategic collaboration with Eli Lilly, fully demonstrating our capabilities in global collaboration. Meanwhile, projects across our oncology and autoimmune pipelines progressed rapidly in China and globally, in line with our commitment to benefit patients worldwide.”

Robust Commercial Growth

Leveraging a diversified and highly competitive product portfolio and strong commercial execution, the Company’s drug sales maintained rapid growth in the first three quarters of 2026, increasing by 41.5% YoY to RMB 1.4 billion.

In 2026, all four approved indications of orelabrutinib were included in the updated National Reimbursement Drug List (NRDL). Orelabrutinib sales grew rapidly following the NRDL inclusion of the first line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) indication, while orelabrutinib maintained its exclusive indication advantage in marginal zone lymphoma (MZL). Additionally, both tafasitamab and zurletrectinib have been approved for marketing and have begun to contribute to sales. Tafasitamab is the first CD19 antibody approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in China, and the next-generation TRK inhibitor, zurletrectinib, has been prescribed in hospitals across China.

Accelerating Innovation

Enhancing Competitive Advantage in Hemato-Oncology

As the first BCL2 inhibitor granted Breakthrough Therapy Designation (BTD) in China, mesutoclax (ICP-248) is advancing five registrational clinical trials. The latest data from the program will be presented at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans from December 12-15, 2026.

1) The registrational Phase III trial of mesutoclax with orelabrutinib in 1L CLL/SLL has completed patient enrollment.
2) The registrational Phase II clinical trial of mesutoclax in BTK inhibitor-treated mantle cell lymphoma (MCL) has completed patient enrollment and received BTD. It is the first BCL2 inhibitor to receive BTD recognition in China.
3) The registrational Phase III clinical trial of mesutoclax in combination with orelabrutinib in r/r MCL is ongoing in China.
4) The head-to-head registrational Phase III trial of mesutoclax with azacitidine versus venetoclax with azacitidine in treatment naïve (TN) acute myeloid leukemia (AML) was initiated in China.
5) The Phase III clinical trial of mesutoclax in combination with orelabrutinib for the treatment of patients with marginal zone lymphoma (MZL) who have received at least one prior therapy has been initiated, and the combination has been granted BTD in China.

In addition, global clinical development of mesutoclax in AML and myelodysplastic syndrome (MDS) is accelerating in China, the U.S., and Australia. The latest data will be presented at the 68th American Society of Hematology (ASH) Annual Meeting in 2026.

Accelerating Autoimmune Pipeline, Building Second Growth Curve

Orelabrutinib

The NDA submission for orelabrutinib in Immune thrombocytopenia（ITP）has been accepted in China, marking orelabrutinib’s first NDA acceptance in an autoimmune indication and a significant milestone in its expansion beyond hematologic malignancies into autoimmune diseases. The Phase III clinical data will be presented at the 68th ASH Annual Meeting in 2026.

The registrational Phase III clinical trial of orelabrutinib in systemic lupus erythematosus (SLE) has been accelerating patient enrollment. Orelabrutinib is the first BTK inhibitor to demonstrate significant efficacy in a Phase IIb clinical trial in SLE.

Two global registrational Phase III clinical trials of orelabrutinib in primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS) are ongoing in collaboration with Zenas. Multiple studies were presented at the 10th Joint ACTRIMS-ECTRIMS Meeting in 2026, fully demonstrating the significant clinical potential of orelabrutinib in SPMS and PPMS.

Two Differentiated Oral TYK2 Inhibitors

Soficitinib (ICP-332) and fadeucravacitinib (ICP-488) have delivered multiple pivotal Phase II/III clinical readouts that met primary endpoints.

Soficitinib

1) The Phase III clinical trial of soficitinib in patients with moderate to severe atopic dermatitis (AD) met primary endpoints.
2) The Phase II portion of the Phase II/III trial in non-segmental vitiligo has met its primary endpoint. The Company will accelerate Phase III clinical trials.
3) The global Phase II clinical trial for prurigo nodularis (PN) has continued patient enrollment in China, U.S. and Europe.
4) The Phase II/III clinical trial for moderate‑to‑severe chronic spontaneous urticaria (CSU) has completed patient enrollment.
5) The Phase II clinical trial for moderate‑to‑severe plaque psoriasis has completed patient enrollment.
6) The Phase II clinical trial in adolescent patients with moderate-to-severe AD has completed patient enrollment.

Fadeucravacitinib

1) The Phase III clinical trial in patients with moderate-to-severe plaque psoriasis achieved primary endpoints.
2) The Phase II clinical trial in cutaneous lupus erythematosus (CLE) is being expedited.
3) The Phase II clinical trial in patients with Sjögren’s syndrome (SS) is ongoing.

Other Autoimmune Pipelines

ICP-054, a novel oral IL-17AA/AF inhibitor, has successfully enrolled healthy volunteers. The single-ascending-dose (SAD) and multiple-ascending-dose (MAD) portions are being conducted in collaboration with Zenas, with Phase I study completion expected by the end of 2026.

ICP-538, the first VAV1 degrader approved to enter clinical trials in China and the second globally, has successfully enrolled patients, with the Phase I clinical study expected to complete by the end of the year. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key signaling protein downstream of the T-cell and B-cell receptors. ICP-538 is being developed for the treatment of hard-to-treat autoimmune diseases, such as inflammatory bowel disease (IBD), SLE, and MS.

ICP-B161, a novel bispecific antibody targeting TL1A and IL-23p19, has been approved for clinical trials for the treatment of autoimmune diseases, including IBD. In preclinical studies, ICP-B161 demonstrated good efficacy, including significant inhibition of colitis-related symptoms.

Accelerating Solid Tumor Pipeline Development

Zurletrectinib, the next-generation TRK inhibitor, was granted priority review for the treatment of pediatric patients (ages 2–12) with solid tumors harboring NTRK fusions, and the NDA application has been accepted.

The Company’s highly differentiated ADC technology platform leverages unique linker-potent payload (LP) technology. Built on this platform, the Company will continue to develop multiple ADC drug candidates with highly differentiated efficacy and safety profiles, bringing a new generation of treatment options to patients with cancer. To date, three innovative ADC candidates have entered clinical development, including the Company’s first bispecific ADC.

1) ICP-B794, a novel B7-H3 targeted ADC, has accelerated Phase I dose-escalation trial, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others.
2) ICP-B208, a novel CDH17-targeted ADC, has entered clinical development, with patient enrollment underway. ICP-B208 is being developed for the treatment of gastrointestinal cancers, including gastric, colorectal, pancreatic ductal adenocarcinoma, and cholangiocarcinoma.
3) ICP-B381, a novel bi-specific ADC targeting PSMA and STEAP1, has entered clinical development in China for the treatment of solid tumors, including prostate cancer. In preclinical studies, ICP-B381 demonstrated robust and dose-dependent antitumor activities.

InnoCare will accelerate the coordinated advancement of innovation, commercialization and globalization, continuing to unlock the value of its innovation globally for the benefit of patients worldwide.

To know more about the detailed financial data and business updates of InnoCare 2026 Q3 results, please log in to https://www.innocarepharma.com/en/investor/home

Conference Call Information

InnoCare will host a conference call at 9:00 a.m. Beijing time in Chinese on Oct. 27, 2026. Participants must register in advance of the conference call through the below link: https://s.comein.cn/y7dbuh3u.

InnoCare Forward-looking Statements

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management’s intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

About InnoCare Pharma

InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing innovative drugs for the treatment of cancers and autoimmune diseases, two therapeutic areas with unmet medical needs worldwide. InnoCare has established comprehensive innovation platforms for drug discovery. To date, the Company has developed a robust product pipeline comprising three approved drugs (orelabrutinib, tafasitamab and zurletrectinib), more than ten innovative drug candidates in clinical development, and multiple programs in preclinical stages. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. For more information about InnoCare, please visit https://www.innocarepharma.com/en and follow us on LinkedIn.

Contact
Media Chunhua Lu 86-10-66609879                         chunhua.lu@innocarepharma.com	Investors 86-10-66609999 ir@innocarepharma.com

Earnings Release: Wednesday, October 28, 2026, Before Market Opens

MONACO, Oct. 26, 2026 (GLOBE NEWSWIRE) — Costamare Inc. (NYSE:CMRE) (the “Company”) announced today that it will release its results for the third quarter ended September 30, 2026 before the market opens in New York on October 28, 2026.

Results Presentation:
A presentation of the Company’s financial results for the third quarter of 2026 will be posted on the Costamare Inc. website (www.costamare.com).

About Costamare Inc.
Costamare Inc. is one of the world’s leading owners and providers of containerships for charter. The Company has 52 years of history in the international shipping industry and a fleet of 69 containerships in the water (including two vessels we have agreed to sell), with a total capacity of approximately 520,000 TEU. The Company also has 22 newbuild containerships under construction and has agreed to acquire two secondhand containerships, which together represent a total capacity of approximately 152,600 TEU. The Company also participates in a leasing business. The Company’s common stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock trade on the New York Stock Exchange under the symbols “CMRE”, “CMRE PR B”, “CMRE PR C” and “CMRE PR D”, respectively.

Forward-Looking Statements
This press release contains “forward-looking statements”. In some cases, you can identify these statements by forward-looking words such as “believe”, “intend”, “anticipate”, “estimate”, “project”, “forecast”, “plan”, “potential”, “may”, “should”, “could”, “expect” and similar expressions. These statements are not historical facts but instead represent only the Company’s belief regarding future results, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in the Company’s Annual Report on Form 20-F (File No. 001-34934) under the caption “Risk Factors”.

Company Contacts:
Gregory Zikos – Chief Financial Officer
Konstantinos Tsakalidis – Business Development, Investor Relations

Costamare Inc., Monaco
Tel: (+377) 93 25 09 40
Email: ir@costamare.com

COSTA MESA, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) announced today that Suman Mookerji, the Company’s senior vice president and chief financial officer, and Christian Prezgay, vice president of financial planning and analysis and investor relations, will participate in the upcoming Baird 2026 Global Industrial Conference on November 10, 2026. Institutional investors are welcome to contact Baird to arrange one-on-one meetings with management.

Additional information will be posted on the Company’s website at www.ducommun.com when available, including a copy of any presentation material.  

About Ducommun Incorporated

Ducommun Incorporated delivers value-added innovative products, aftermarket and manufacturing solutions to customers in the aerospace, defense and space markets and aspires to contribute to the advancement of those industries. Founded in 1849, the Company specializes in two core areas — Electronic Systems and Structural Systems — to produce complex products and components for commercial aircraft platforms and mission-critical military and space programs. For more information, visit Ducommun.com.

Contacts
Suman Mookerji, Senior Vice President and Chief Financial Officer
657.335.3665, smookerji@ducommun.com

LONGUEUIL, Quebec, Oct. 26, 2026 (GLOBE NEWSWIRE) — Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) is pleased to provide an update on its ongoing exploration program at the wholly owned Wabamisk Property in the Eeyou Istchee James Bay region of Québec (see Figures 1 to 4).

Salient Facts

• A 3-kilometre by 5-kilometre gold-bearing vein field has been recognized over the Rosa-Dome Sector. The area is largely untested by drilling.
• A new gold showing (“Ginger”) highlights the excellent exploration potential over the 15-kilometre distance separating the Rosa and Fortin zones.
• Extensive surface field work continues to prepare a minimum 7,000-metre diamond drilling program, planned to start later this year. Since June 2026, 8 significant gold showings have been discovered through prospecting and mechanical stripping. Over the past several weeks alone, at least 9 new mineralized outcrops have been found in the Dome Sector (results pending).

This year’s field program has significantly expanded the scale of the gold potential at Wabamisk. In particular, the Rosa-Dome Sector appears to be part of a multi-kilometre gold-bearing vein field characterized by:

• An extensive quartz vein system, which returned numerous high-grade gold results.
• Widespread tourmaline and iron carbonate (ankerite) alteration.
• Sulphide mineralization (mostly arsenopyrite, pyrite, pyrrhotite).
• A network of subparallel major structures.
• A variety of host rock types, dominated by sheared mafic volcanics and/or gabbro, and metasediments.
• Continuous trends of induced polarization (“IP”) anomalies.

The Rosa-Dome Vein Field (see Figures 5 to 7, Photos 1 to 7)

This vein field currently consists of five (5) distinct mineralized zones sharing common features, as summarized in the table below. Their cumulative length reaches at least 5.4 kilometres. The geological framework and limited drilling to date suggest these zones can be significantly extended along strike and at depth. The potential for additional discoveries in this area is considered very high, supported by new prospecting results, soil and/or till surveys, and a new geophysical IP survey in progress.

The multi-kilometre width and the greenschist metamorphic context of the Rosa-Dome structural corridor underscore a potential for kilometre-scale vertical continuity. It appears to be part of a much broader system that extends at least to the Fortin Zone, 15 kilometres further to the east, and likely over a 30-kilometre strike length. This corridor roughly corresponds to the major tectonic boundary between the La Grande volcano-plutonic subprovince and the Opinaca metasedimentary subprovince.

The Rosa-Dome sector displays several key features that characterize the Val-d’Or vein field in Québec, spatially located near or directly associated with a fault network marking the transition between the Abitibi volcano-plutonic subprovince and the Pontiac metasedimentary subprovince The Val-d’Or district is broadly characterized by gold-bearing quartz veins mostly hosted in sheared mafic to intermediate volcanic rocks and intrusions. These veins and their wallrocks contain arsenopyrite and/or pyrite sulphides, with tourmaline and iron carbonate as the dominant alteration assemblage.

New Gold Showing between Rosa and Fortin (see Figure 8, Photo 8)

A new gold showing (the Ginger Showing), recently uncovered by prospecting, underscores the discovery potential between the Rosa-Dome sector and the Fortin Zone. Preliminary results include up to 3.71 g/t Au in grab samples and 1.40 g/t Au over 2.0 m in a channel sample. Apparent mineralized thickness reaches about 10 metres.

Mineralization consists of disseminated to semi-massive arsenopyrite hosted in metasedimentary rocks with quartz veining. Albitic alteration has been observed, indicating possible strike continuity with the antimony-gold Fortin Zone, which is associated with a thick albitic unit (see press release of May 20, 2026ⁱ). Additional work, including mechanical stripping, is underway to expand the showing, which remains open in all directions. The Ginger Showing correlates well with a 5-kilometre-long IP anomaly and a strong arsenic-antimony anomaly in soil.

Grab samples are selective by nature, unlikely to represent average grades, and may not represent true underlying mineralization.

Overview of the 2026 Field Program (see Figure 9)

• Soil geochemistry: 5,517 samples collected; results pending for 3,573 samples.
• Rock geochemistry: 1 355 grab and channel samples collected; results pending for 249 samples. Active prospecting phase still in progress.
• Till survey: collection of 102 samples underway, mainly in the Dome Sector.
• IP survey: 144 line-kilometres in progress, mainly over the Dome Sector.
• Mechanical stripping: currently underway over the Rosa Zone, Dome Sector and Ginger Showing.
• Diamond drilling: a minimum of 7,000 metres will be drilled starting later this year to expand the Rosa Zone and to test Rosa’s western extensions, the Dome Sector and new targets.

Initial results from the summer program were reported in the press release of September 9, 2026ⁱⁱ.

About Wabamisk

The Wabamisk Property is a wholly owned project comprising 784 claims covering 415.2 km². This includes 73 claims recently added to the Property by map designation. The contiguous Wabamisk East Property (205 claims, 108.5 km²) is also being explored for gold and lithium. Together, the Wabamisk and Wabamisk East projects provide exposure to a strategic 59-kilometre-long strike position in one of the most prospective greenstone belts in the James Bay region.

Wabamisk lies 13 kilometres east of the Clearwater Property (Fury Gold Mines Ltd), 42 kilometres northeast of the Whabouchi lithium deposit (Rio Tinto – Nemaska Lithium), and 70 kilometres south of the Éléonore gold mine (Dhilmar Ltd). Major powerlines pass through or close to the Property’s eastern end, and the North Road highway passes 37 kilometres to the south. The nearest town is Nemaska, a Cree municipality 55 kilometres to the southwest.

Analytical protocols and project management

Sawed channel samples and grabs were sent to Actlabs Laboratories in Val-d’Or, Québec. Several batches of rock samples were also sent to MSALABS in Val-d’Or. Gold was analyzed using PhotonAssay™ technology, a non-destructive X-ray analytical method that directly measures gold content in crushed rock samples. Samples were also analyzed for a 48-element suite using ICP. Azimut applies industry-standard QA/QC procedures to its drilling and prospecting programs. All batches sent for analysis included certified reference materials, blanks and field duplicates. Soil samples were sent to Actlabs Laboratories for analysis using method 1A6-50 on a 50-gram sample with cyanide extraction and ICP-MS finish for gold, and method UT-2-30g (aqua regia digestion with ICP and ICP-MS finish) for trace elements.

The project is under the direction of Alain Cayer (P.Geo.), Azimut’s Project Manager.

Qualified person

Dr. Jean-Marc Lulin (P.Geo.), Azimut’s President and CEO, prepared this press release and approved the scientific and technical information disclosed herein, including the previously reported results presented in the figures and table supporting this press release. He is acting as the Company’s qualified person within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

About Azimut

Azimut is a leading mineral exploration company with a solid reputation for target generation and partnership development. The Company controls strategic land positions for gold, copper, nickel and lithium in Québec. Azimut is focused on several key high-impact projects:

• Wabamisk and Wabamisk East (100% Azimut), which host the Fortin Zone (antimony-gold), Rosa Zone (gold), Dome Sector (gold), and Lithos Zone (lithium).
• Elmer (100% Azimut), which hosts the resource-stage Patwon Deposit (gold) (311,200 oz Indicated and 513,900 oz Inferredⁱⁱⁱ).
• Kukamas (KGHM option), which hosts the Perseus Zone (nickel-PGE).
• Nickel North Corridor (SOQUEM option) for its nickel-copper-PGE potential.
• Corvet and Kaanaayaa (Centerra option) for their gold and copper potential.

Azimut uses a pioneering approach to big data analytics (the proprietary AZtechMine™ expert system), enhanced by extensive exploration know-how. The Company’s competitive edge is based on systematic, regional-scale data analysis. Azimut maintains rigorous financial discipline and a strong balance sheet.

Azimut has two strategic investors among its shareholders, Centerra Gold Inc. and Agnico Eagle Mines Limited, which hold approximately 12.7% and 11%, respectively, of the Company’s issued and outstanding shares.

Contact and Information

Jean-Marc Lulin, President and CEO
Tel.: (450) 646-3015 – Fax: (450) 646-3045

Jonathan Rosset, Vice President Corporate Development
Tel.: (604) 202-7531
info@azimut-exploration.com        www.azimut-exploration.com

Cautionary note regarding forward-looking statements

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events related to the drilling results from the Wabamisk Property. To the extent that any statements in this press release contain information that is not historical, the statements are essentially forward-looking and are often identified by words such as “consider”, “anticipate”, “expect”, “estimate”, “intend”, “project”, “plan”, “potential”, “suggest” and “believe”. The forward-looking statements involve risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Many factors could cause such differences, particularly volatility and sensitivity to market metal prices, the impact of changes in foreign currency exchange rates and interest rates, imprecision in reserve estimates, recoveries of gold and other metals, environmental risks including increased regulatory burdens, unexpected geological conditions, adverse mining conditions, community and non-governmental organization actions, changes in government regulations and policies, including laws and policies, global outbreaks of infectious diseases, and failure to obtain necessary permits and approvals from government authorities, as well as other development and operating risks. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this document. The Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, other than as required to do so by applicable securities laws. The reader is directed to carefully review the detailed risk discussion in our most recent Annual Report filed on SEDAR+ for a fuller understanding of the risks and uncertainties that affect the Company’s business.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

______________________
ⁱ Azimut Continues to Expand the Fortin Antimony-Gold Zone, Wabamisk Property, James Bay Region, Québec
ⁱⁱ Azimut Accelerates District-Scale Gold Exploration at Wabamisk
iii Technical Report and Initial Mineral Resource Estimate for the Patwon Deposit, Elmer Property, Québec, Canada, prepared by Martin Perron, P.Eng., Chafana Hamed Sako, P.Geo., Vincent Nadeau-Benoit, P.Geo. and Simon Boudreau, P.Eng. of InnovExplo Inc., dated January 4, 2024. The initial MRE comprises Indicated resources of 311,200 ounces in 4.99 million tonnes grading 1.93 g/t Au and Inferred resources of 513,900 ounces in 8.22 million tonnes grading 1.94 g/t Au.

ROSA-DOME VEIN FIELD, WABAMISK PROPERTY, JAMES BAY REGION, QUÉBEC

Table 1: Rosa-Dome Vein Field – Preliminary Description – North to South

Zone or Prospect	Length (km)	Salient gold results to date	Mineralogy / Alteration	Host rocks	Geochemical footprint in soil (B horizon)	Geophysics	Drilling to date (meterage, # of holes)
ROSA	1.4 (open)	46.41 g/t Au / 3.5m (D) 9.29 g/t Au / 5.0m (D) 1.29 g/t Au / 28.8m (D) 30.17 g/t Au / 4.0m (C) 93.9 g/t Au / 0.35m (G)	Visible gold, Py, Po, Asp, (Cp) Quartz veins Tourmaline Ankerite Chlorite	Metasediments, (intermediate to mafic volcanics)	As, Ag, Bi, (Au, Cu, Sb, W)	Corridor of strong IP anomalies	6,651.2 m (46)
ROSA WEST	1.5 (to be validated)	New showings: Up to 2.88 g/t Au (G) Up to 2.36 g/t Au (G)	Quartz veins Po, (Cp)	Metasediments	As, Ag, Au, Bi, Cu	Corridor of strong IP anomalies	None
K	0.5 (open)	52.4 g/t Au (G) 19.3 g/t Au (G) 1.8 g/t Au / 2.8m (D) 1.7 g/t Au / 3.0m (C)	Asp, Po, Py, (Cp) Quartz veins Calcite	Contact gabbro / metasediments	Not covered	Strong IP anomalies (historical survey) EM axis in the vicinity	523.27 m (7) Historical holes
PP-51 East PP-51 West	1.8 (open)	1.0 g/t Au / 17.0m (D) 2.6 g/t Au / 2.3m (D) 8.54 g/t Au (G) 5.24 g/t Au (G)	Asp, Po, Py, (Cp) Quartz veins Tourmaline	Contact mafic-ultramaficintrusion/ basalt; metasediments	Partly covered As, Au, (Sb, W)	Strong IP anomalies (historical survey)	1,473 m (11) Historical holes
DOME A	0.7 (open)	9.33 g/t Au / 0.9m (D) 2.49 g/t Au / 0.91m (D)	Asp, Po, (Cp) Quartz veins Tourmaline Carbonate	Sheared gabbro, metasediments	Not covered	Strong IP anomalies in the vicinity (historical survey); EM anomaly east of Dome A	473.3 m (7) Historical holes
At 500m NNE At 1.5 km ENE		New showings: Up to 4.78 g/t Au (G) Up to 6.3 g/t Au (G)
DOME C DOME NE FISCHER	1.0 (open)	1.3 g/t Au / 7.5m (D) 17.7 g/t Au / 1.0m (C) 14.26 g/t Au/1.0m (C) 80.71 g/t Au (G)	Asp, Po, (Cp) Quartz veins Tourmaline Carbonate	Gabbro, basalt, metasediments	Au, Ag, As, Cu, Sb, W, (Bi)	Strong IP anomalies (historical survey) EM anomaly	717.3 m (6) Historical holes
At 1 km SW		New showing: Up to 5.56 g/t Au (G)

Notes:
Location: See Figures 5 to 9
Azimut’s results since 2025 in bold
Grab samples are selective by nature, unlikely to represent average grades, and may not represent true underlying mineralization.
Asp: arsenopyrite; Py: pyrite; Po: pyrrhotite; Cp: chalcopyrite
D: Drill core interval; C: Channel interval; G: Grab sample

Newport Beach, CA, Oct. 26, 2026 (GLOBE NEWSWIRE) — Bimergen Energy Corporation (NYSE American: BESS), a developer, owner, and operator of utility-scale and distributed battery energy storage systems, today announced that its wholly owned subsidiary, Emergen Commodities LLC, has filed an application with the Public Utility Commission of Texas (PUCT) for an Option 2 Retail Electric Provider (REP) certificate. The application represents a step toward adding retail electricity capabilities to Bimergen’s energy infrastructure business. Subject to regulatory approval and applicable market requirements, the certification would enable Bimergen, through Emergen Commodities, to supply electricity directly to qualifying data center customers in Texas.

“Pursuing retail electric provider certification is a step toward broadening Bimergen’s capabilities in the Texas energy market,” said Cole Johnson, Co-CEO of Bimergen Energy. “The substantial electricity requirements of large data centers present a compelling commercial opportunity. By building on our energy infrastructure expertise and adding retail electricity supply capabilities, we believe we can position Bimergen to participate in this growing market and create additional opportunities for long-term value.”

Supplying electricity to large data center customers could generate substantial revenue for Emergen Commodities and its parent company, Bimergen Energy. The significant and ongoing electricity requirements of these facilities present an opportunity to establish recurring revenue streams through customer supply agreements.

Texas’ Option 2 certification provides a pathway to serve specifically identified customers contracting for at least one megawatt of capacity. Subject to regulatory approval and applicable market requirements, the certification would establish a foundation for Emergen Commodities to participate in this segment of the Texas retail electricity market.

In parallel with the regulatory process, Bimergen is working with multiple counterparties to provide credit support for large data center loads. These efforts are intended to support the electricity supply arrangements needed to serve customers with substantial power requirements and advance Bimergen’s proposed retail electricity business.

Bimergen’s broader strategy focuses on advancing battery energy storage projects through development, technology partnerships, and collaboration with capital providers. The proposed retail electricity capability would complement that strategy by expanding the ways Bimergen participates in the energy market and connects its infrastructure expertise with electricity needs.

“We are focused on translating this opportunity into a commercially viable business that can contribute meaningfully to Bimergen’s long-term growth,” said Bob Brilon, Co-CEO of Bimergen Energy. “Our work to establish the necessary credit support and advance the regulatory process reflects a disciplined approach to entering this market. We see the potential for substantial revenue from serving large electricity customers while continuing to advance our core battery energy storage business.”

Emergen Commodities filed its application with the Public Utility Commission of Texas (PUCT) on October 5, 2026, under Docket No. 60368. The application is currently under regulatory review and remains subject to PUCT approval.

About Bimergen Energy Corporation

Bimergen Energy Corporation (NYSE American: BESS) is a U.S.-based energy infrastructure developer, asset owner, and operator focused on utility-scale and distributed battery energy storage systems (BESS). The Company develops projects designed to enhance grid reliability, support renewable energy integration, and provide flexible energy solutions across key U.S. power markets. Bimergen works with technology providers and capital partners to advance projects through development, construction, and long-term operation. For more information about Bimergen Energy, please visit www.bimergen.com.

Commercial & Industrial Electricity Inquiries

Bimergen Energy welcomes inquiries from data center operators, commercial and industrial (C&I) businesses, and other large electricity consumers in Texas interested in exploring electricity pricing and long-term power supply opportunities.

To discuss potential electricity pricing and supply arrangements, please contact:

Email: info@bimergen.com
Website: www.bimergen.com

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the proposed retail electricity business, anticipated benefits of REP certification, the potential to supply electricity directly to data center customers, efforts to arrange credit support for large data center loads, potential substantial and recurring revenue, market participation, business expansion, and long-term value creation. These statements reflect current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.

These risks include the timing and outcome of regulatory review, satisfaction of certification and market participation requirements, the ability to establish commercially viable customer and supplier arrangements, the ability to secure sufficient credit support for large data center loads, the timing and scale of customer electricity demand, electricity price volatility, financing availability, project execution, and other risks described in the Company’s Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this announcement. Bimergen Energy Corporation undertakes no obligation to update these statements except as required by applicable law.

Media Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447)
BESS@redchip.com

ZUG, Switzerland, Oct. 26, 2026 (GLOBE NEWSWIRE) — Lithium Argentina AG (“Lithium Argentina” or the “Company“) (TSX: LAR) (NYSE: LAR) today announced that it has repurchased $200 million aggregate principal amount of its convertible senior notes due January 2027 (the “2027 Notes“) in privately negotiated transactions with a limited number of qualified institutional buyers for approximately $198 million in cash, plus accrued interest. The repurchases were funded with cash on hand, including proceeds of the $180 million strategic investment from Ganfeng Lithium Group Co., Ltd. (“Ganfeng”) that closed on September 15, 2026. Following the repurchases, approximately $59 million aggregate principal amount of the 2027 Notes remains outstanding. Lithium Argentina intends to repay the remaining balance at or before its January 15, 2027 maturity from cash on hand, which exceeded $100 million following the repurchases, further reducing its overall debt.

“Repurchasing the majority of the 2027 Notes with cash is the next step in deleveraging and strengthening our balance sheet,” said Sam Pigott, Chief Executive Officer. “With no other corporate-level debt maturing until 2032 and Cauchari-Olaroz generating strong cash flow, we are well positioned to allocate capital in the way that best serves our shareholders.”

Pursuant to the terms of the indenture governing the 2027 Notes, the Company may from time to time repurchase 2027 Notes through privately negotiated transactions or otherwise, depending on market conditions, applicable securities law and other factors. There can be no assurance as to the timing or amount of any further repurchases.

This news release is for informational purposes only and does not constitute an offer to purchase, or the solicitation of an offer to sell, any 2027 Notes or other securities.

The transactions described in this news release were effected through privately negotiated agreements with a limited number of holders located outside Canada. No offer to purchase 2027 Notes has been made, nor is any such offer being made, directly or indirectly, in Canada, and no resident of Canada is being solicited to participate in any such transaction.

ABOUT LITHIUM ARGENTINA

Lithium Argentina jointly owns and manages the Cauchari-Olaroz lithium brine operation in the Jujuy province of Argentina and is advancing the PPG lithium brine development in the Salta province of Argentina. Lithium is a key material used in the production of lithium-ion batteries, electric vehicles, and battery energy storage systems (BESS). The Company currently trades on the TSX and on the NYSE under the ticker “LAR”.

For further information contact:
Investor Relations
Telephone: +1 778-653-8092
Email: kelly.obrien@lithium-argentina.com
Website: http://www.lithium-argentina.com

FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” and “forward-looking statements” (which we refer to collectively as forward-looking information) under the provisions of applicable securities legislation. Forward-looking information can be identified by the use of words such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “propose”, “potential”, “target”, “intend”, “could”, “might”, “should”, “believe”, “scheduled”, “implement” and similar words or expressions. All statements, other than statements of historical fact, are forward-looking information. Forward-looking information in this news release include, without limitation, information with respect to the following matters or the Company’s expectations relating to such matters: the anticipated benefits of the repurchases; the Company’s ability to repurchase or repay the remaining 2027 Notes at or before maturity; whether, when and on what terms the Company may repurchase additional 2027 Notes; the Company’s intention to repay the remaining 2027 Notes from cash on hand; the Company’s expected debt levels and financial position following such repayment; and the Company’s capital allocation priorities.

Forward-looking information may involve known and unknown risks, assumptions and uncertainties which may cause the Company’s actual results or performance to differ materially. This information reflects the Company’s current views with respect to future events and is necessarily based upon a number of assumptions that, while considered reasonable by the Company today, are inherently subject to significant uncertainties and contingencies, and accordingly, the Company can give no assurance that these assumptions and expectations will prove to be correct. With respect to forward-looking information included in this news release, the Company has made assumptions regarding, among other things: current technological trends; the business relationship between the Company and Ganfeng; ability to fund its operations; the ability to operate in a safe and effective manner; uncertainties relating to obtaining and/or maintaining mining, exploration, development, environmental and other permits or approvals in Argentina; demand for lithium; impact of increasing competition in the lithium business, including the Company’s competitive position in the industry; general economic conditions; stability and support of legislative, regulatory and community environment in the jurisdiction where it operates; estimates of and changes to market prices for lithium and commodities; estimates costs for the project or operation; estimates of mineral resources and mineral reserves, including whether mineral resources will ever be developed into mineral reserves; reliability of technical data; and the ability to achieve full production; and accuracy of budget and estimates. Forward-looking information also involves known and unknown risks that may cause actual results to differ materially, these risks include, among others: the anticipated benefits of the repurchases may not be realized as contemplated, or at all; the Company may not be able to repurchase or repay the remaining 2027 Notes as contemplated, or at all; the Company’s plans for PPG and PPG may not be implemented as contemplated, or at all; the benefits of RIGI may not be realized as anticipated, or at all; the operations may not operate and produce as planned; cost overruns; market prices affecting development of the operation; risks associated with co-ownership arrangements; risks with ability to successfully secure adequate financing if necessary; risks to the growth of the lithium markets; lithium prices; inability to obtain any future required governmental permits and that operations may be limited by government-imposed limitations; technology, cyber security and artificial intelligence risk; inability to achieve and manage expected growth; political risk associated with foreign operations, including co-ownership arrangements with foreign domiciled partners; emerging and developing market risks; operational risks; changes in government regulations; changes in environmental requirements; failure to obtain or maintain necessary licenses, permits or approvals; insurance risk; receipt and security of mineral property titles and mineral tenure risk; changes in project or operation parameters; uncertainties associated with estimating mineral resources and mineral reserves, including uncertainties regarding assumptions underlying such estimates; whether mineral resources will ever be converted into mineral reserves; opposition to the Company’s projects; geological or technical or processing problems; liabilities and risks; health and safety risks; unanticipated results; unpredictable weather; unanticipated delays; reduction in demand for lithium; inability to generate profitable operations; restrictive covenants in debt instruments; intellectual property risks; dependency on key personnel; currency and interest rate fluctuations; and volatility in general market and industry conditions. Additional risks, assumptions and other factors are set out in the Company’s management discussion analysis and most recent Annual Report on Form 20-F, copies of which are available on SEDAR+ at www.sedarplus.ca

Although the Company has attempted to identify important risks and assumptions, given the inherent uncertainties in such forward-looking information, there may be other factors that cause results to differ materially. Forward-looking information is made as of the date hereof and the Company does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. Accordingly, readers are cautioned not to place undue reliance on forward-looking information. 

Company Announcement

Copenhagen, 26 October 2026
No. 65/2026

ISS A/S, a leading workplace experience and facility management company, announced on 19 February 2026 a new share buyback programme, see company announcement no. 10/2026. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbour Regulation.

Through the programme, ISS wishes to redistribute excess cash to shareholders. The purpose of the share buy-back programme is to (i) reduce the share capital and (ii) meet obligations arising from ISS’ share-based incentive programmes.

Under the programme, ISS will repurchase shares for a maximum consideration of DKK 3.1 billion, including approx. DKK 1.25 billion related to the completed first tranche, over a 12-month period from 19 February 2026 to 22 February 2027 at the latest, both days inclusive. The second tranche of up to DKK 1.85 billion commenced on 11 August 2026 and will complete no later than 22 February 2027.

The following transactions have been made under the programme:

	Number of shares	Average purchase price, DKK	Transaction value, DKK
Accumulated, last announcement	7,115,873	264.88	1,884,869,399
19 October 2026	54,000	295.94	15,980,760
20 October 2026	30,000	293.55	8,806,500
21 October 2026	53,000	295.16	15,643,480
22 October 2026	28,102	291.45	8,190,328
23 October 2026	52,000	288.48	15,000,960
Accumulated under the programme	7,332,975	265.72	1,948,491,427

Following the transactions stated above, ISS A/S owns a total of 7,081,350 treasury shares corresponding to 4.43% of the total share capital.

In accordance with the Market Abuse Regulation, the details of each transaction made under the share buyback programme are enclosed.

For investor enquiries
Michael Vitfell-Rasmussen, Head of Group Investor Relations, +45 53 53 87 25
Anne Sophie Riis, Senior Investor Relations Manager, +45 30 52 94 68

For media enquiries
Charlotte Holm, Head of External Communication, +45 41 76 19 89

ISS is a leading, global provider of workplace and facility service solutions. In partnership with customers, ISS drives the engagement and well-being of people, minimises the impact on the environment, and protects and maintains property. ISS brings all of this to life through a unique combination of data, insight and service excellence at offices, factories, airports, hospitals and other locations across the globe. ISS has more than 325,000 employees around the globe, who we call “placemakers”. In 2025, Group revenue was DKK 84.7 billion. For more information on the ISS Group, visit www.issworld.com

Attachments

• ISS announcement – SBB week 43
• Appendix_Company_Announcement_NO_43-2026

RENO, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE American: LODE) (“Comstock” and the “Company”) is pleased to announce that the Company’s CEO, Corrado De Gasperis, and CFO, Judd Merrill will provide an overview of our third quarter 2026 financial results and current business updates on Wednesday, November 4, 2026, at 4:30pm ET. We invite our investors and all other interested parties to register for the webinar at the link below.

Date: Wednesday, November 4, 2026
Time: 4:30pm ET
Register: Webinar Registration

The call includes a live presentation and a Q&A session. You may submit your question(s) beforehand in the registration form (linked above) or by email at: ir@comstockinc.com.

About Comstock Inc.

Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, and other critical minerals, primarily from end-of-life photovoltaics and renewable fuels, chemicals and animal feedstocks, primarily derived from proprietary crops and other forms of woody biomass for energy.

To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

For investor inquiries:
Judd B. Merrill, Chief Financial Officer
Tel (775) 413-6222
ir@comstockinc.com

For media inquiries:
Zach Spencer, Director of External Relations
Tel (775) 847-7573
media@comstockinc.com

Forward-Looking Statements 

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “forecast,” “seek,” “target,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances and business combinations; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings of equity or debt securities; and future working capital needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company or any other issuer.

• Combined company expected to advance differentiated oral obesity franchise led by CX11, a clinical-stage, once-daily oral small-molecule GLP-1 receptor agonist (“RA”), and CX12, a preclinical oral small-molecule amylin receptor agonist.
• CX11 has demonstrated clinically meaningful weight loss and a generally favorable tolerability profile across Phase 2 obesity studies in the United States. Following an End-of-Phase 2 meeting, Corxel US has aligned with the U.S. Food and Drug Administration (“FDA”) on key elements of CX11’s regulatory path and Phase 3 trial design.
• Institutional investors have committed to a private investment in public equity (“PIPE”) of approximately $300 million, with participation from new and existing investors including RTW Investments, New Enterprise Associates (NEA), SR One, Mirae Asset Capital Life Science, HBM Healthcare Investments (Cayman) Ltd., Nantahala Capital, Coastlands Capital, LifeSci Venture Partners, Invus, TCGX, RA Capital Management, Propel Bio, SilverArc Capital and a large healthcare mutual fund.
• Transaction expected to provide approximately $377 million in gross proceeds (prior to the payment of transaction costs and assuming no redemptions by Amanat shareholders).
• Business combination expected to be completed in the first half of 2027. Proceeds expected to support the company through 2029, including funding the planned global Phase 3 development program for CX11 in obesity.

BERKELEY HEIGHTS, N.J. and WESTFIELD, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) — Corxel Pharmaceuticals, Inc. (“Corxel US”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for obesity and related cardiometabolic conditions, and Amanat Acquisition Corp (Nasdaq: AMAN) (“Amanat”), a publicly traded special purpose acquisition company, today announced they have entered into a definitive business combination agreement.

Upon completion of the proposed transaction, Corxel US will become a wholly owned subsidiary of the combined public company. The combined public company is expected to operate under a new name and have its common stock listed on the Nasdaq Capital Market under a new ticker symbol, in each case to be announced before closing. The current management of Corxel US is expected to continue leading Corxel US while a search for a U.S.-based Chief Executive Officer is underway. A new Chief Executive Officer of the combined company is expected to be hired prior to or upon the closing of the transaction.

In addition to approximately $75 million held in Amanat’s trust account, the transaction includes commitments for a concurrent, oversubscribed PIPE that is expected to result in total gross proceeds of approximately $300 million, subject to adjustment pursuant to the reduction mechanism described below. The PIPE includes participation from new and existing investors including RTW Investments, New Enterprise Associates (NEA), SR One, Mirae Asset Capital Life Science, HBM Healthcare Investments (Cayman) Ltd., Nantahala Capital, Coastlands Capital, LifeSci Venture Partners, Invus, TCGX, RA Capital Management, Propel Bio, SilverArc Capital and a large healthcare mutual fund. Certain investors may receive pre-funded warrants in lieu of shares, priced at the per share price less the exercise price payable upon exercise. Subject to specified conditions, PIPE investors may also reduce their respective subscription obligations on a one-for-one basis by acquiring and not redeeming Amanat shares in the open market or in privately negotiated transactions prior to the shareholder meeting, with a corresponding reduction in their respective purchase prices under the PIPE.

“This transaction represents another important milestone in Corxel Group’s corporate evolution and reflects the significant progress we have made in building a globally competitive cardiometabolic pipeline,” said Sandy Mou, Executive Director and Chief Executive Officer of Corxel Group. “Corxel Group was built on the belief that our most promising pipeline deserves the focus and resources to reach its full potential. We believe the proposed business combination will mark Corxel US’s transition into an independent public company, positioning it to pursue its long-term growth strategy with greater visibility and broader access to the public markets.”

Kevin Xie, Ph.D., Chief Financial Officer of Corxel US, added, “This transaction represents an important step in establishing Corxel US as a publicly traded, obesity-focused biopharmaceutical company with the capital strength and strategic flexibility to advance CX11 through global pivotal development. We believe CX11’s clinical profile, including the weight loss and favorable tolerability observed across multiple studies, positions it as a potentially differentiated, next-generation oral GLP-1 therapy. Following an End-of-Phase 2 meeting, we have aligned with the FDA on key elements of CX11’s regulatory path and Phase 3 trial design, and we are preparing to advance CX11 into global pivotal Phase 3 trials. Together with CX12, CX11 provides the foundation for an oral obesity franchise built to deliver meaningful benefits to a broad global patient population.”

Pavan Cheruvu, M.D., Chief Executive Officer and Director of Amanat, added, “We established Amanat to identify compelling healthcare businesses that could benefit from our team’s operating, clinical, and capital-markets experience. We believe Corxel US brings together an experienced global development team, a late-stage oral GLP-1 program supported by a substantial clinical dataset, a favorable tolerability profile and a defined regulatory path, as well as an emerging oral amylin program. We believe the proposed transaction can provide the resources and public-company platform needed to advance this portfolio and create long-term value for patients and shareholders.” 

Building a Differentiated Oral Obesity Franchise

Corxel US is advancing a portfolio of oral product candidates designed to address important limitations of current injectable and oral obesity therapies and expand the number of patients who can access effective, convenient, and scalable treatment options.

Its lead product candidate, CX11, is an investigational, once-daily, oral small-molecule GLP-1 RA being developed for obesity, type 2 diabetes, and related cardiometabolic conditions. CX11 has been evaluated across an extensive clinical development program in the United States and Asia and has demonstrated clinically meaningful weight loss and a generally favorable tolerability profile.

In a U.S. Phase 2 obesity trial, CX11 achieved mean body-weight reduction of up to 11.5% at Week 36 under the efficacy estimand. CX11 also demonstrated a generally favorable GI tolerability and safety profile throughout the 36-week double-blind treatment period. Across the CX11 dosing cohorts, rates of nausea ranged from 33% to 34%, vomiting from 12% to 16%, diarrhea from 4% to 12% and constipation from 2% to 12%. The most commonly reported adverse events were GI-related and were generally mild to moderate in severity. No severe cases of nausea, vomiting, diarrhea or constipation were reported. GI adverse events occurred primarily during dose escalation and gradually subsided during the maintenance period. The overall treatment-discontinuation rate due to GI adverse events was 5.0%.

Following an End-of-Phase 2 meeting, Corxel US has aligned with the FDA on key elements of CX11’s regulatory path and Phase 3 trial design and plans to advance CX11 into global Phase 3 development.

An ongoing Phase 1b study evaluating higher doses of CX11 is expected to provide additional clinical data in the first half of 2027 and is intended to explore potential efficacy upside supported by the product candidate’s pharmacokinetic and tolerability profile observed to date.

Corxel US is also developing CX12, an investigational oral small-molecule amylin receptor agonist. Multiple lead candidates are currently under evaluation, with IND-enabling activities ongoing to target an investigational new drug application for CX12 in the first half of 2027. 

Transaction Overview

The proposed business combination and concurrent PIPE are expected to provide approximately $377 million (prior to the payment of transaction costs and assuming no redemptions by Amanat’s shareholders) in gross proceeds to the combined company. The net proceeds from the proposed transaction are expected to support the company through 2029 and to fund the global Phase 3 development program for CX11 in obesity.

Corxel Pharmaceuticals Limited (“Corxel Group”), the current parent company of Corxel US, is expected to receive equity consideration in the combined company in the form of common stock and pre-funded warrants.

The transaction is specifically limited to Corxel US and the obesity-focused business and assets included in the definitive business combination agreement. Corxel US is currently part of the broader Corxel Group. Other Corxel Group entities and assets held outside Corxel US, including Corxel HK and JX10, Corxel HK’s clinical-stage acute ischemic stroke program, are not included in the transaction and will remain outside the combined public company.

The boards of directors of Corxel US and Amanat have each approved the proposed transaction. The transaction is expected to close in the first half of 2027, subject to customary closing conditions, including, among other things, approval by Amanat’s shareholders, receipt of required approvals from Corxel US and Corxel Group stakeholders, effectiveness of the applicable registration statement, satisfaction of Nasdaq listing requirements and receipt of any required regulatory approvals.

 Additional information regarding the proposed transaction, including a copy of the definitive business combination agreement, will be included in a Current Report on Form 8-K to be filed by Amanat with the U.S. Securities and Exchange Commission (“SEC”) and will be available at the SEC’s website at www.sec.gov.

Advisors

Leerink Partners is acting as lead placement agent, and Evercore ISI, Guggenheim Securities, Cantor and LifeSci Capital are acting as placement agents for the PIPE financing. Leerink Partners is acting as capital markets advisor to Amanat.

Cooley LLP is serving as legal counsel to Corxel US and Corxel Group. Goodwin Procter LLP is serving as legal counsel to Amanat. Latham & Watkins LLP is serving as legal counsel to the placement agents. 

About Corxel US

Corxel US is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for obesity and related cardiometabolic conditions. Its lead product candidate, CX11, is an investigational, once-daily oral small-molecule GLP-1 receptor agonist that has completed Phase 2 clinical development in the United States and Phase 3 clinical development in Asia, demonstrating clinically meaningful weight loss and a generally favorable tolerability profile. Following an End-of-Phase 2 meeting, Corxel US has aligned with the FDA on key elements of CX11’s regulatory path and Phase 3 trial design. Corxel US is also advancing CX12, an investigational oral small-molecule amylin receptor agonist in preclinical development.

Corxel US is currently part of the Corxel Group. Corxel US and Corxel HK are separate entities within that group. The transaction with Amanat relates only to Corxel US and the obesity-focused business and assets specified in the definitive transaction documents. Corxel HK, JX10 and other assets held outside Corxel US are not part of the transaction. 

About Amanat Acquisition Corp

Amanat Acquisition Corp is a blank check company incorporated as a Cayman Islands exempted company for the purpose of completing a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination.

Amanat intends to focus on opportunities in healthcare and healthcare-related industries that can benefit from the experience and capabilities of its management team and board of directors. Amanat is sponsored by Amanat Sponsor Holdings LLC and is led by Sandeep C. Kulkarni, M.D., Chairman of the Board; Pavan Cheruvu, M.D., Director and Chief Executive Officer; and Nicholas Fernandez, Chief Financial Officer. Amanat’s board of directors also includes Brad Middlekauff, Patrick Crutcher and Rakhi Kumar, bringing extensive experience across biotechnology investing, company building, financial leadership, corporate governance, business development, and capital markets.

Important Information About the Proposed Transaction and Where to Find It

The proposed transaction will be submitted to Amanat’s shareholders for consideration. In connection with the proposed transaction, Amanat intends to file with the SEC a registration statement on Form S-4 (the “Registration Statement”), which will include a preliminary proxy statement for the solicitation of proxies from Amanat shareholders with respect to the proposed business combination and other matters to be described in the Registration Statement and a prospectus relating to securities expected to be issued in the proposed transaction.

After the Registration Statement has been filed and declared effective, Amanat expects to mail or otherwise make available to shareholders entitled to vote a definitive proxy statement/prospectus and other relevant materials. This announcement is not a substitute for the Registration Statement, proxy statement/prospectus or any other document that may be filed with the SEC in connection with the proposed transaction.

AMANAT SHAREHOLDERS AND OTHER INTERESTED PERSONS SHOULD REVIEW CAREFULLY, WHEN AVAILABLE, THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS, ANY AMENDMENTS OR SUPPLEMENTS, AND OTHER RELEVANT SEC FILINGS BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, BECAUSE THOSE MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES.

When available, these documents may be obtained without charge through the SEC’s website at www.sec.gov or by directing a request to Amanat Acquisition Corp, 153 Central Avenue, C/O 56, Westfield, New Jersey 07091. 

Participants in the Solicitation

Amanat, Corxel US and certain of their respective directors, executive officers and other members of management and employees may be considered participants in the solicitation of proxies from Amanat shareholders in connection with the proposed transaction.

Information regarding Amanat’s directors and executive officers, including their interests by security holdings or otherwise, is available in Amanat’s SEC filings, which may be obtained without charge through the SEC’s website at www.sec.gov or by directing a request to Amanat Acquisition Corp, 153 Central Avenue, C/O 56, Westfield, New Jersey 07091. Additional information concerning the persons who may be considered participants and a description of their direct and indirect interests in the proposed transaction will be included in the Registration Statement and proxy statement/prospectus when filed. Shareholders, potential investors and other interested persons should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. 

No Offer or Solicitation

This announcement is provided solely for informational purposes and is not, and under no circumstances is to be construed as, a proxy statement, a solicitation of any proxy, consent or authorization, a recommendation concerning any securities or the proposed transaction, a prospectus, an advertisement or a public offering of the securities described herein in the United States or any other jurisdiction. This announcement shall not constitute an offer to sell or exchange, or a solicitation of an offer to buy or exchange, or a recommendation to purchase, any securities, in any jurisdiction, or the solicitation of any vote, consent or approval in any jurisdiction in connection with the proposed business combination or any related transactions, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful.

No sale of securities will be made in any jurisdiction where the offer, solicitation or sale would be unlawful before registration or qualification under applicable securities laws. Any offering of securities will be made only through a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or pursuant to an available exemption from registration.

THE SEC AND ANY STATE SECURITIES COMMISSION HAVE NOT APPROVED OR DISAPPROVED THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT, PASSED ON THE MERITS OF THE PROPOSED TRANSACTION OR DETERMINED THAT THIS ANNOUNCEMENT IS ACCURATE OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL. 

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of applicable U.S. federal securities laws. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would” and similar expressions, although not all forward-looking statements contain these identifying words. These statements include, but are not limited to, statements regarding the proposed business combination and PIPE financing; the anticipated timing, structure, proceeds, ownership, capitalization, management, listing and expected benefits of the proposed transaction; statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity; the parties’ ability to complete the transaction and satisfy closing conditions; the anticipated use of proceeds and cash runway; and the development, regulatory, manufacturing and commercialization plans for CX11, CX12 and other product candidates, including the design, timing, enrollment and results of clinical trials and the potential efficacy, safety, tolerability, convenience, scalability and commercial opportunity of those product candidates.

These statements reflect current expectations and assumptions as of the date of this announcement, are provided for illustrative purposes only and are not guarantees or predictions of future performance.

Actual results may differ materially because of numerous risks and uncertainties, many of which are difficult or impossible to predict or are beyond the parties’ control. These risks include, but are not limited to: the possibility that the proposed transaction is delayed, restructured or not completed; failure to obtain shareholder, regulatory or other approvals or to satisfy other closing conditions; the amount of Amanat shareholder redemptions; changes in the amount of cash available to the combined company; failure to satisfy Nasdaq listing requirements; the occurrence of events giving rise to termination rights under the definitive agreement; litigation or other proceedings relating to the transaction; costs and disruption arising from the announcement or completion of the transaction; adverse changes in business, market, economic, political or regulatory conditions; volatility in the combined company’s securities; dilution resulting from the transaction or future financings; the outcome of any legal proceedings that may be instituted against Amanat or Corxel US related to the proposed business combination; the inability of the parties to successfully or timely consummate the proposed business combination and other related transactions, including the risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business combination and other related transactions; and the combined company’s ability to realize the anticipated benefits of the transaction and manage growth. 

Additional risks include uncertainties inherent in drug research and development, clinical trials and regulatory review; delays or difficulties in patient enrollment, manufacturing or supply; clinical results that do not support continued development or approval; the timing and outcome of interactions with regulatory authorities; competition; dependence on third-party manufacturers, clinical research organizations and other service providers; intellectual-property risks; the ability to attract and retain key personnel; and the need for additional financing. This list is not exhaustive.

Further information about risks and uncertainties will be included in the Registration Statement and proxy statement/prospectus for the proposed transaction and in other filings made by Amanat with the SEC, including under the captions addressing risk factors. Readers should not place undue reliance on forward-looking statements, which speak only as of the date made. Except as required by applicable law, Amanat and Corxel US do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

Corxel US Investor Relations
Ray Lyu
Ray.Lyu@corxelbio.com

Corxel US Media Relations
Madelin Hawtin
Mhawtin@lifescicomms.com 

Amanat Acquisition Corp
Nicholas Fernandez
Nfernandez@amanat.bio 

• TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile supportive of systemic administration in an outpatient setting
• With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months and multiple participants continuing in active follow-up
• TeLuRide-008, an ongoing adaptive Phase 2/3 trial of EIK1001 in NSCLC, actively enrolling, with a prespecified interim analysis for dose selection anticipated in 2H 2027

MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of updated data for EIK1001 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.

“These updated results presented at ESMO from the squamous NSCLC cohort build on the mature non-squamous cohort data presented at ASCO and further support the potential of adding EIK1001 to pembrolizumab and chemotherapy,” said Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon. “The observed response and disease control rates, as well as a 12.9-month median duration of response, are encouraging, with several patients remaining in active follow-up. These findings support continued evaluation of this combination for patients with advanced NSCLC.”

EIK1001 Clinical Update:

Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in participants with advanced NSCLC demonstrates potentially durable effect of EIK1001 in combination with standard of care, as well as a tolerability profile supportive of systemic administration in an outpatient setting, a potential key differentiator of EIK1001 from previous TLR7/8 targeted therapies.

In TeLuRide-005, 72 participants with previously untreated stage 4 NSCLC received intravenous EIK1001 once-weekly (QW) combined with standard of care pembrolizumab plus histology-appropriate chemotherapy once every third week (Q3W). After 8 cycles, EIK1001 administration was reduced to Q3W. The maximum treatment duration is 2 years (up to 35 cycles) for EIK1001 in combination with pembrolizumab, with pemetrexed continued at the discretion of the Investigator for non-squamous participants.

At the July 13, 2026, safety data cutoff, among the safety evaluable population (n=72: 39 non-squamous; 33 squamous), the combination of EIK1001 with pembrolizumab and chemotherapy was generally well tolerated, with an adverse event (AE) profile similar to standard-of-care alone. Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 48.6% of participants, and TRAEs led to treatment discontinuation in 6.9%. The most common Grade 3 or higher TRAEs were neutropenia (30.6%), anemia (9.7%), and thrombocytopenia (9.7%). Cytokine release syndrome events were all low-grade (Grade 1, n=5; Grade 2, n=2), and there were no Grade 3 or higher events. There were no TRAEs that led to death. This profile was sufficient to support administration in an outpatient setting during the ongoing trial.

Among the efficacy-evaluable population (n=65: 36 non-squamous; 29 squamous), EIK1001 treatment in combination with pembrolizumab and chemotherapy pooled data with a median follow-up of 17.2 months resulted in a 63.1% objective response rate (ORR) and 89.2% disease control rate (DCR) at the efficacy data cutoff of October 1, 2026. Objective responses were observed across all PD-L1 tumor proportion score (TPS) subgroups. Among participants in the squamous cohort, an ORR of 72.4% and a DCR of 100% were observed, respectively, with a median follow-up of 12.7 months and a median duration of response (DOR) of 12.9 months at the efficacy data cutoff. Among participants in the non-squamous cohort, an ORR of 55.6% and a DCR of 80.6% were observed, respectively, with a median follow-up of 17.9 months. The median DOR in the non-squamous cohort was 11.2 months at the efficacy data cutoff.

In addition to the TeLuRide-005 data presented at ESMO, Eikon is currently conducting a Phase 2/3 registrational trial of EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy in systemic therapy-naïve participants with stage 4 non-squamous or squamous NSCLC, also known as TeLuRide-008 (NCT07365319). Eikon expects to conduct a first interim analysis to select the single dose of EIK1001 to take forward for the remainder of this trial in the second half of 2027.

About Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com.

About NSCLC
Lung cancer is one of the most common cancers globally, with NSCLC making up 80% to 85% of all lung cancer cases. NSCLC is often diagnosed at advanced stages when treatment options are more limited and there remains significant unmet medical need in this patient population. The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The current standard of care for stage 4 NSCLC, combining immune checkpoint inhibitors (ICIs) (e.g., pembrolizumab) plus histology-appropriate chemotherapy confers significant clinical benefit over chemotherapy alone, yet many patients progress nonetheless, highlighting the large unmet medical need in the management of this disease.

About EIK1001
EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8, designed to stimulate both innate and adaptive immune responses. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced malignancy. This mechanism may complement the anti-tumor immune response engendered by PD-(L)1 blockade. EIK1001 has been studied in over 600 participants and observed to be well-tolerated to date, both as a monotherapy and in combination with PD-(L)1-specific antibody-based therapy.

About TeLuRide-005
TeLuRide-005 (NCT06246110) is a multicenter, open-label trial of once-weekly (QW) systemically administered EIK1001 in combination with standard of care, once every third week (Q3W) pembrolizumab and histology-appropriate chemotherapy in first-line, treatment-naïve participants with stage 4 NSCLC. Enrollment completed in the first quarter of 2026.

Forward-Looking/Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the potential to further develop Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives, including Eikon’s anticipated presentations at the 2026 ESMO Congress; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.

These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 13, 2026, and in other public filings with the SEC in the future.

As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts:

Investors
Alfred “Freddie” Bowie, Ph.D., CFO
ir@eikontx.com

Media
Colin Sanford
colin@bioscribe.com